EUCTR2017-002878-38-NL进行中（未招募）1 期
Abatacept to Silence anti-Citrullinated protein Antibody-expressing B cells in Rheumatoid Arthritis - ASCARA
eiden University Medical Center0 个研究点目标入组 46 人开始时间: 2017年9月12日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria. Each patient must:
- •-have a diagnosis of rheumatoid arthritis according to the revised 2010 EULAR/ACR criteria for classification of RA
- •-have a positive test for the presence of anti-citrullinated protein antibodies (ACPA) in serum as determined by routine clinical assay.
- •-have adequate hematologic function (ANC = 4000 cells/µL, platelet count = 150000/µL, and hemoglobin = 10 g/dL (corresponding to 6.2 mmol/L)
- •-have serum creatinine concentrations < 1.5 mg/dl and/or a normal creatinine clearance
- •-be at least 18 years of age
- •-if a female patient is of childbearing potential, agree to: comply with effective contraceptive measures, use adequate contraception since the last menses, use adequate contraception during the study, have a negative pregnancy test within one week of study entry
- •-be willing to receive a booster vaccination against tetanus toxoid three to four weeks prior to randomization
- •-be able and willing to give written informed consent prior to entry in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 31
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study. Any patient who has:
- •-been previously treated with either abatacept and/or methotrexate or another csDMARD
- •-been previously treated with a kinase inhibitor
- •-been previously treated with rituximab or another B-cell depleting agent
- •-been previously treated with a biological DMARD
- •-received intra-articular or systemic glucocorticoid injections or has required treatment for acute RA flare (not being part of a regular therapeutic regimen) within four weeks prior to randomization or requires narcotic analgesics other than those accepted by the investigator for analgesia (e.g. paracetamol, codeine, tramadol)
- •-been tested negative for anti citrullinated protein antibodies
- •-contraindications for a booster vaccination against tetanus toxoid prior to randomization to the treatment arms; if a patient refuses booster vaccination but has detectable numbers of tetanus toxoid-specific B cells circulating in peripheral blood prior to the baseline visit, the patient can still be allowed to participate in the study at the judgement of the investigator.
- •-evidence of any other major chronic inflammatory disease (i.e. psoriasis, psoriatic arthritis, spondyloarthritis or inflammatory bowel disease)
- •-evidence of poorly controlled diabetes, history of clinically significant pulmonary disease including interstitial lung disease or methotrexate-induced lung disease, poorly controlled asthma or a history of severe life-threatening asthma attacks, history of active tuberculosis, history of latent tuberculosis without adequate medical treatment, liver cirrhosis or fibrosis, significant active infection or any underlying diseases that could predispose the subject to infections
- •-liver function abnormality (total bilirubin = 1.5 x the upper limit of normal range, AST, ALT = 3 x upper limit of normal range)
- •-concurrent treatment with an experimental drug or who has participated in another clinical trial with an investigational drug within 30 days prior to study entry
- •-pre-existing sensory or motor polyneuropathy = Grade 2 according to NCI CTC
- •-past or current history of neoplasms, except for curatively treated non-melanoma skin cancer, adequately treated in situ carcinoma of the cervix or another cancer curatively treated and with no evidence of disease for at least 10 years
- •-significant cardiac disease, cardiac arrhythmia (Lown Grade = III), uncontrolled hypertension or recent history of myocardial ischemia
- •-Pregnant or nursing women
研究者
相似试验
已完成
不适用
Abatacept to Silence anti-Citrullinated protein Antibody-expressing B cells in Rheumatoid ArthritisRheumatoid arthritisNL-OMON50283eids Universitair Medisch Centrum46
已完成
4 期
Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)Rheumatic DiseasesRheumatoid ArthritisNCT03492658Leiden University Medical Center46
已完成
不适用
Rapid test for rheumatoid arthritisCTRI/2020/10/028596Diabetes Research Society150
已完成
不适用
The application of anti-cyclic citrullinated peptide autoantibody and soluble HLA-DR tests to the detection of early rheumatoid arthritis in New Zealand patients.Inflammatory and Immune System - Rheumatoid arthritisRheumatoid arthritisACTRN12606000277549isa Stamp80
进行中（未招募）
不适用
Aprepitant in the prevention of cisplatin-induced delayed emesis: a double-blind randomized study - Aprepitant for cisplatin-induced delayed emesisEUCTR2008-001339-37-ITAZIENDA OSPEDALIERA S. MARIA DI TERNI560